Access Pharmaceuticals Presents New Combination Data On The Company’s Angiolix(R) Therapeutic Monoclonal Antibody

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) presented new data this week on its proprietary humanized monoclonal antibody, Angiolix, which confirmed that Angiolix(R) binds with high affinity to the its target, lactadherin, resulting in anti-angiogenesis and significant tumor growth inhibition in MCF-7 and MX-1 breast cancer xenografts. Its anticancer activity is greatly enhanced when given in combination with chemotherapy.

More: continued here

Filed under: Cancer on January 27th, 2009